|
Name of compound | Source | Name of the source | MOA | Clinical trials against cancer | Reference |
|
Flavopiridol | Plant | Amoora rohituka, Dysoxylum binectaiferum | Blocking the progression at gap 1 (G1) or gap2 (G2) phase of the cell cycle | Phase I clinical trial: dose-dependent toxicity Phase II clinical trial patients: colorectal cancer, prostate cancer, renal cell carcinoma, small cell lung carcinoma, non-lymphoma, Hodgkin's, and chronic lymphocytic leukemia | [52, 53] |
|
4-Ipomeanol | Plant | Ipomoeca batatas | Inhibits DNA topoisomerase I and induces delay in the cell cycle at gap G-1 phase or S phase | Clinical trial: lung cancer-specific antineoplastic agent | [54] |
|
Ingenol mebutate | Plant | Euphorbia peplus | — | Under clinical trial Discontinued production due to increase risk of nonmelanoma skin cancer | [30] |
|
Elliptinium acetate: a derivative of ellipticine | Plant | Bleekeria vitensis | Topoisomerase II inhibitor and intercalating agent, inhibiting DNA replication and RNA and protein synthesis | Under clinical trial | [55] |
|
TNP-470: an analog of fumagillin | Fungi | Aspergillus fumigates | Inhibits angiogenesis | Clinical trials for its antiangiogenic agent to treat breast, prostrate, brain cancer, and Kaposi sarcoma | |
|
CKD-732 (O-(4-dimethylaminoethoxycinnamoyl)fumagillol) | Fungi | Aspergillus fumigates | Inhibits angiogenesis | Phase I: in combination was checked for tolerability and safety Phase II: recommended dose determined | [56–59] |
|
Irofulven synthetic analogue of illudin S | Fungi | Omphalotus illudens | Alkylating agent | Irofulvene in treating patients with stage III or stage IV pancreatic cancer. Clinical trial was conducted. Details not available. | [60, 61] |
|
Plinabulin | Marine fungus | Aspergillus ustus | | Clinical trial: positive result | [62, 63] |
|